Generic placeholder image

Infectious Disorders - Drug Targets

Author(s): Hristina Tsanovska*, Iana Simova, Vladislav Genov, Todor Kundurzhiev, Jordan Krasnaliev, Vladimir Kornovski, Nikolai Dimitrov and Toni Vekov

DOI: 10.2174/1871526522666220303121209

DownloadDownload PDF Flyer Cite As
Hydroxychloroquine (HCQ) Treatment for Hospitalized Patients with COVID- 19

Article ID: e030322201650 Pages: 8

  • * (Excluding Mailing and Handling)

Abstract

Objective: Studies have indicated that hydroxychloroquine (HCQ) exerts antiviral effects against SARS-CoV-2 in vitro. However, trials regarding its effects on patients are very controversial. This study aims to evaluate the efficacy of (HCQ) in the treatment of hospitalized patients with COVID-19.

Methods: We prospectively enrolled 260 patients hospitalized for COVID-19 in Heart and Brain Center of Excellence- Pleven, Bulgaria, for the period from November 6 to December 28, 2020. This study is not randomized, which we compensated for with Propensity Score Matching. Patients in the HCQ group were given HCQ 200 mg 3 times a day (600mg daily) for the duration of their hospitalization plus conventional treatment, while those in the control group were given conventional treatment only. The primary endpoints were transferred to the intensive care unit, needed for mechanical ventilation, and in-hospital death.

Results: Of the 260 COVID-19 patients, 178 (68.5%) were male and the mean age was of 63.78 ± 12.45 years, with the most prevalent comorbidity hypertension (68.5%). We had two subgroups: treated with HCQ and conventional treatment (128 patients) and treated with conventional treatment only (132 patients). In the primary analysis, patients in the HCQ group presented with fewer comorbidities and were younger than the group without HCQ. Patients treated with HCQ demonstrated a significant benefit in the primary endpoints compared to those without HCQ, namely, transferred to ICU – 20 (20,8%) vs. 41 (36.9%), p=0.011, need for mechanical ventilation 13 (13.4%) vs. 33 (28.2%), p=0.009 and in-hospital death 14 (10.9%) vs. 35 (26.5%), p=0,001, respectively. We repeated this analysis with PSM, where 70 matched pairs were identified. Regarding the primary endpoints, we found again a statistically significant difference between the groups. Comparing transferring to ICU, better outcomes were presented in the HCQ group: 8 (17.4%) vs. 27 (44.3%), with p= 0.003. Besides, a smaller proportion of the patients needed mechanical ventilation: 6 (12.8%), compared to the control group, 23 (35.4%), p= 0.007. Notably, patients from the HCQ group died during hospitalization: 8 (11.4%) in comparison with 19 (27.1%) from the control group, p= 0.018.

Conclusion: Patients treated with HCQ demonstrated a significant benefit in the primary endpoints in our study, namely, transfer to the intensive care unit, need for mechanical ventilation, and in-hospital death. HCQ improves prognosis in hospitalized patients with COVID-19.

Keywords: COVID- 19 treatment, hydroxychloroquine, heart and brain, acute respiratory syndrome, an antimalarial drug.

Graphical Abstract

[1]
World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it (Accessed on: April 6, 2020).
[2]
Subramanya SH. Czyż DM, Acharya KP, Humphreys H. The potential impact of the COVID-19 pandemic on antimicrobial resistance and antibiotic stewardship. Virusdisease 2021; 32(2): 1-8.
[http://dx.doi.org/10.1007/s13337-021-00695-2] [PMID: 34056051]
[3]
Abd-Elsalam S, Kobtan A, El-Kalla F, et al. A 2-week Nita-zoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: A single center experience. Medicine (Baltimore) 2016; 95(24): e3879.
[http://dx.doi.org/10.1097/MD.0000000000003879] [PMID: 27310977]
[4]
Shehata MA, Talaat R, Soliman S, Elmesseri H, Soliman S, Abd-Elsalam S. Randomized controlled study of a novel triple nitazoxanide (NTZ)-containing therapeutic regimen versus the traditional regimen for eradication of Helicobacter pylori infec-tion. Helicobacter 2017; 22(5): e12395.
[http://dx.doi.org/10.1111/hel.12395] [PMID: 28524341]
[5]
Chen X, Geiger JD. Janus sword actions of chloroquine and hydroxychloroquine against COVID-19. Cell Signal 2020; 73: 109706.
[http://dx.doi.org/10.1016/j.cellsig.2020.109706] [PMID: 32629149]
[6]
Singh B, Ryan H, Kredo T, Chaplin M, Fletcher T. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. Cochrane Database Syst Rev 2021; 2(2): CD013587.
[http://dx.doi.org/10.1002/14651858] [PMID: 33624299]
[7]
National institute of Health. COVID-19 treatment guidelines, 2022. Available from: https://www.covid19treatmentguidelines.nih.gov/ (Accessed on April 10, 2020).
[8]
Horby P, Mafham M, Linsell L, et al. Effect of hydroxychloro-quine in hospitalized patients with Covid-19. N Engl J Med 2020; 383(21): 2030-40.
[http://dx.doi.org/10.1056/NEJMoa2022926] [PMID: 33031652]
[9]
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30(3): 269-71.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]
[10]
Catteau L, Dauby N, Montourcy M, et al. Low-dose hy-droxychloroquine therapy and mortality in hospitalised patients with COVID-19: A nationwide observational study of 8075 par-ticipants. Int J Antimicrob Agents 2020; 56(4): 106144.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.106144] [PMID: 32853673]
[11]
Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D. Efficacy of hy-droxychloroquine in patients with COVID-19: Results of a ran-domized clinical trial. Renmin Hospital of Wuhan University, Wuhan 430060, China. Medrxiv 2020.
[http://dx.doi.org/10.1101/2020.03.22.20040758]
[12]
Wong YK, Yang J, He Y. Caution and clarity required in the use of chloroquine for COVID-19. Lancet Rheumatol 2020; 2(5): e255.
[http://dx.doi.org/10.1016/S2665-9913(20)30093-X] [PMID: 32518920]
[13]
Duca A, Piva S, Focà E, Latronico E, Rizzi M. Step-wise management approach to COVID-19 patients based on clinical severity. Brescia-COVID Respiratory Severity Scale Algorithm 2020. Available from: www.mdcalc.com/brescia-covid-respiratory-severity-scale-bcrss-algorithm (Accessed on April 6, 2020.
[14]
Mehra MR, Desai SS, Ruschitzka F, Patel AN. Retracted: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: A multinational registry analysis. 2020.
[http://dx.doi.org/10.1016/S0140-6736(20)31180-6]
[15]
Surgisphere. Governments and WHO changed COVID-19 policy based on suspect data from a tiny US companies. 2022. Available from: https://www.theguardian.com/world/2020/jun/03/covid-19-surgisphere-who-world-health-organization-hydroxychloroquine Accessed April 06, 2020.
[16]
Bhandari S, Singh A, Sharma R, et al. Characteristics, treatment outcomes and role of hydroxychloroquine among 522 COVID-19 hospitalized patients in Jaipur city: An epidemio-clinical study. J Assoc Physicians India 2020; 68(6): 13-9.
[PMID: 32610873]
[17]
Lagier J-C, Million M, Gautret P, Colson P, Cortaredona S. Out-comes of 3,737 COVID-19 patients treated with hydroxychlo-roquine/azithromycin and other regimens in Marseille. Travel Med Infect Dis 2020; 36: 101791.
[http://dx.doi.org/10.1016/j.tmaid.2020.101791]
[18]
Rosenberg ES, Dufort EM, Udo T, et al. Association of treat-ment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA 2020; 323(24): 2493-502.
[http://dx.doi.org/10.1001/jama.2020.8630] [PMID: 32392282]
[19]
Chivese T, Musa OAH, Hindy G, et al. Efficacy of chloroquine and hydroxychloroquine in treating COVID-19 infection: A me-ta-review of systematic reviews and an updated meta-analysis. Travel Med Infect Dis 2021; 43: 102135.
[http://dx.doi.org/10.1016/j.tmaid.2021.102135] [PMID: 34265436]